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Background: The life expectancy of untreated non-small-cell lung cancer (NSCLC) is dismal, 
while treatment for NSCLC improves survival. The presence of comorbidities is thought to 
play a significant role in the decision to treat or not treat a given patient. We aim to evaluate the 
association of comorbidities with the survival of patients treated for NSCLC.
Methods: We performed a retrospective study of patients aged ≥66 years with invasive NSCLC 
between the years 2007 and 2011 in the Surveillance, Epidemiology, and End Results Kentucky 
Cancer Registry. Comorbidity was measured using the Klabunde Comorbidity Index (KCI), 
and univariate and multivariate logistic regression models were used to measure association 
between receiving treatment and comorbidity. Kaplan–Meier plots were constructed to estimate 
time-to-event outcomes.
Results: A total of 4014 patients were identified; of this, 94.9% were white and 55.7% were 
male. The proportion of patients who did not receive any treatment was 8.7%, 3.9%, 19.1%, 
and 23.5% for stages I, II, III, and IV, respectively (p<0.0001). In multivariate analysis, older 
age, higher stage, and higher comorbidity (KCI ≥3) were associated with a lower likelihood of 
receiving any treatment. The median overall survival (OS) for untreated and KCI=0 was 17.7 
months for stages I and II, 2.3 months for stage III, and 1.3 months for stage IV. The median 
OS for treated and KCI=0 was 58.9 months for stages I and II, 16.8 months for stage III, and 
5.8 months for stage IV (p<0.01). Treatment was an independent predictor of OS in multivariate 
analysis that included KCI scores.
Conclusion: Our data suggest that lung cancer patients may derive a survival benefit from 
therapies, regardless of the presence of comorbidities, although the degree of benefit seems to 
decrease with higher KCI scores.
Keywords: non-small-cell lung cancer, Klabunde, cancer, comorbidity index, lung cancer
Introduction
Non-small-cell lung cancer (NSCLC), when untreated, proves invariably deadly in 
the vast majority of patients within 1 year.1 NSCLC is diagnosed at advanced stages 
(III or IV) in 70% of the cases in the USA, and 19%–24% of the individuals with 
advanced NSCLC are never treated.2,3 Furthermore, untreated NSCLC accounts for 
55% of all untreated advanced cancers in the USA.3 There are multiple reasons why 
patients do not receive therapy; however, comorbidity consistently stands out as a 
reported predictor for lack of therapy for NSCLC patients.4–6 Comorbidity burden 
has been described to be higher along with the high prevalence of smoking in lung 
cancer compared with other types of solid tumors.7 The presence of comorbidities 
can influence treatment selection due to organ damage or increased risk of adverse 
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effects. Currently, it remains unclear if the comorbidity bur-
den alone is predictive of outcome in a lung cancer patient or 
only when it affects patient’s performance status.5 Similarly, 
there are limited data regarding the actual benefit of treating 
lung cancer in patients with a high comorbidity burden. In 
this study, we aim to evaluate the association of comorbidi-
ties with the treatment and the survival of NSCLC patient 
population along with the degree of benefit from treatment 
in those patients with comorbidities.
Methods
Patient population and eligibility criteria
A retrospective cohort study of patients aged ≥66 years diag-
nosed with invasive NSCLC stages I through IV between the 
years 2007 and 2011 in the state of Kentucky, was performed 
using data from the Surveillance, Epidemiology, and End 
Results (SEER) registry linked to claim files from the US 
Medicare database (SEER-Medicare). Medicare provides 
insurance to elderly Americans and this study included 
patients who had continuous Medicare part A (hospital insur-
ance) and part B (medical insurance) coverage 12 months prior 
and 6 months after lung cancer diagnosis or death, whichever 
came first. We excluded patients with health maintenance 
organization coverage in the previous 12 months, those with 
Medicare eligibility due to end-stage renal disease or disabil-
ity, and those with a concurrent diagnosis of cancer within 3 
months of lung cancer diagnosis (Figure 1). The chair granted 
an Institutional Review Board approval after an expedited 
review application at the University of Louisville, Kentucky.
Cancer treatment
Treatment information was obtained from both registry and 
claims data. Surgical treatment data were obtained using the 
SEER Kentucky Cancer Registry (KCR) surgery codes and 
claims data from the SEER Medicare Provider Analysis and 
Review (MEDPAR) and Carrier Claims – National Claims 
History (NCH) files. Radiation treatment and chemotherapy 
data were obtained using KCR treatment codes, MEDPAR, 
NCH, and the SEER outpatient claim files. Furthermore, the 
SEER Durable Medical Equipment and Prescription Drug 
Event files were evaluated to determine the use of chemo-
therapy. A full description of the specific codes used can be 
found in Tables S1 and S2.
Variables of interest
Age at the time of diagnosis, race/ethnic information and 
the stage at diagnosis were obtained from KCR. Race/
ethnicity was categorized into 3 groups: White, black, and 
other. Comorbidity burden on diagnosis was measured 
using the lung cancer-specific Klabunde Comorbidity Index 
(KCI).8 The KCI, a continuous comorbidity index based 
on the comorbid conditions identified by Charlson index 
that incorporates the diagnostic and procedure data from 
physician claims, was converted into a categorical variable 
of increasing severity of comorbidity: no and very low 
comorbidity (KCI=0), low comorbidity (KCI=1), moder-
ate comorbidity (KCI=2), and high comorbidity (KCI≥3).8 
Poverty at the residential census tract level was categorized 
in 4 groups according to the percentage of residents with an 
income below the US federal poverty line (<8%, 8%–15%, 
15%–30%, or >30%). Education at the residential census 
tract level was categorized into 4 groups based on the 
proportion of adult residents (≥25 years old) with less than 
high school education (<15%, 15%–25%, 35%–35%, and 
>35%). Geographic origin of the patient was classified into
metropolitan versus rural origin and Appalachian versus
Figure 1 Flow diagram – patient population.
Abbreviations: HMO, health maintenance organization; KCR, Kentucky Cancer Registry; PEDSF, patient entitlement and diagnosis summary file; SEER, Surveillance, 
Epidemiology, and End Results.
Study cases
4014 cases
Removing HMO coverage
4014 (861 removed)
Applying medicare eligibility (disability)
4875 ( 6 removed)
Dual eligibility (part AB-before and after)
4881 (269 removed)
Matching SEER KCR data with PEDSF data
5150 (91 in KCR but not in PEDSF)
5241 cases (2007–2011)
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non-Appalachian origin according to the US Census Bureau 
definitions.
Outcome variables included treatment status and overall 
survival (OS) from the time of diagnosis. The treatment 
status was a dichotomous variable, defined as any treatment 
(including surgery, radiation, chemotherapy, or a combination 
of those) versus no treatment. OS was measured from the day 
of diagnosis to the date of death or the date of last contact.
Statistical analysis
Descriptive analysis and χ² tests were used to assess the 
association between treatment status and covariates. Multi-
variate logistic regression models were used to explore the 
association between receiving treatment and comorbidity, 
while accounting for the potential confounding effect of 
other covariates. The interaction effects and the goodness of 
fit were examined. The final model only included the signifi-
cant covariates. Kaplan–Meier estimates and log-rank tests 
were calculated to examine the survival curves of various 
treatment and comorbidity combinations. Cox regression 
survival models were fitted to identify the significant factors 
associated with survival while controlling for other covari-
ates. All tests were 2-sided with a 0.05 significance level. 
SAS 9.3 was used for all analysis.
Results
We identified 4014 cases of invasive NSCLC as eligible for 
analysis. Most patients (94.9%) were Caucasian, and 55.7% 
were male. Approximately half of the patients lived in rural 
areas (48%). KCI scores were 0 (no or very low comorbid-
ity), 1 (low comorbidity), 2 (moderate comorbidity), and ≥3 
(severe comorbidity) in 46.8%, 29.1%, 10.8%, and 13.3% 
of the study sample, respectively.
Receiving lung cancer treatment
The proportion of patients by stage who did not receive 
any treatment for lung cancer were 8.7%, 3.9%, and 19.1% 
for stage I, stage II, and stage III, respectively (p<0.0001). 
A total of 49.1% of stage IV patients did not receive any 
chemotherapy and 23.5% of this cohort did not receive any 
treatment modality (p<0.0001). Compared with the treated 
individuals, the untreated population had a higher proportion 
of patients >75 years old, diagnosed at stage IV, residing in 
rural areas, having higher comorbidity index scores, and 
more likely to live in areas of lower education levels. Of the 
patients with a KCI≥3%, 25.4% were untreated, compared 
with 16.4% of patients with KCI=0%, 15.7% with KCI=1%, 
and 18.2% with KCI=2 (p<0.0001) (Table 1). Across all 
stages, the proportion of patients with high comorbidity (KCI 
≥3) was similarly distributed (15.2% in stages I–II, 12.9%
in stage III, and 12% in stage IV). In multivariate analysis,
older age, more advanced stage, higher comorbidity index,
and residency in rural areas were significantly associated
with a lower likelihood of receiving lung cancer treatment.
Survival analysis
In patients with KCI=0, the median OS for the untreated 
group was 17.7 months for stages I and II, 2.3 months for 
stage III, and 1.3 months for stage IV. For KCI=0 patients 
who received treatment, the median OS was 58.9, 16.8, 
and 5.8 months for stages I and II, III, and IV, respectively 
( Figures 2–4). In patients with KCI ≥3, the median OS for 
the untreated group was 6.1, 1.6, and 1.2 months for stages 
I and II, III, and IV, respectively. For the KCI ≥3 patients 
who received any treatment, the median OS was 22.9, 10.9, 
and 3.7 months for stages I and II, III, and IV, respectively 
 (Figures 2–4). In multivariate Cox regression models, age, 
gender, stage, KCI scores, and receiving treatment were 
associated with survival (Table 2). In particular, higher 
comorbidity was independently associated with lower OS 
(HR=1.51 for KCI≥3 vs KCI=0; 95% CI 1.363–1.679; 
p<0.001).
Within each comorbidity index level, patients who 
received no therapy had worse survival than those who 
received any therapy (Table 3).
Discussion
Our study confirms the previously reported association 
between the presence of comorbidities and lower likelihood 
of receiving cancer treatment.4–6 However, conflicting data 
were found with regard to the association between comor-
bidities and on survival of lung cancer patients. Luchtenborg 
et al9 found that severe comorbidity had a large detrimental 
impact on the survival of lung cancer patients who undergo 
curative lung resection. In contrast, a retrospective cohort 
study from the Netherlands showed that the negative effect 
of comorbidity on survival in nonsurgical candidates was 
present only in patients treated with chemotherapy.10 In an 
analysis of all cancer cases diagnosed between 1992 and 
2005 included in the US SEER database, Edwards et al7 
found that the influence of comorbidities on the probability 
of both cancer-specific and non-cancer-related mortality was 
smaller for lung cancer compared with other cancers. Our 
study adds to the body of evidence suggesting that comorbidi-
ties influence physicians’ decision to recommend treatment 
for NSCLC, and that comorbidity levels may correlate with 
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other clinical factors influencing treatment choices, such as 
performance status.
Despite the role of comorbidity assessments in the choice 
of treatments, limited data are available about the actual 
benefit of lung cancer therapy in patients with high comor-
bidity burden. Patients who are more sick are more likely to 
be excluded from standard clinical trials, leaving clinicians 
with little objective assessments of treatment benefits in the 
setting of high comorbidities. Furthermore, when considering 
the toxicity profile of chemotherapy, the intensity of treatment 
is limited by organ function, which can be directly impacted 
by the presence of comorbidities. Patients with higher burden 
of comorbidities, as determined by KCI score of 3 or higher, 
constituted ~15% of our study population. In this group, we 
Table 1 Characteristics of patients by treatment status
Variable Total No treatment Received treatment p-value
N % N % N %
Age group (years) <0.001
66–70 1241 30.9 144 11.6 1097 88.4
71–75 1151 28.7 181 15.7 970 84.3
76–80 907 22.6 170 18.7 737 81.3
81–85 525 13.1 144 27.4 381 72.6
86+ 190 4.7 67 35.3 123 64.7
Grade <0.001
Well-differentiated 198 4.9 23 11.6 175 88.4
Moderately differentiated 981 24.4 103 10.5 878 89.5
Poorly differentiated 1141 28.4 152 13.3 989 86.7
Undifferentiated 56 1.4 6 10.7 50 89.3
Unknown 1638 40.8 422 25.8 1216 74.2
Race 0.112
White 3809 94.9 665 17.5 3144 82.5
Black 193 4.8 41 21.2 152 78.8
Other 12 0.3 0 0.0 12 100.0
Sex 0.745
Male 2235 55.7 397 17.8 1838 82.2
Female 1779 44.3 309 17.4 1470 82.6
Histology type 0.049
Adenocarcinoma 1862 46.4 331 17.8 1531 82.2
Squamous 1907 47.5 346 18.1 1561 81.9
Other 245 6.1 29 11.8 216 88.2
Metro 0.002
Non-metro 1927 48.0 376 19.5 1551 80.5
Metro 2087 52.0 330 15.8 1757 84.2
Appal 0.016
Non-Appalachian 2840 70.8 473 16.7 2367 83.3
Appalachian 1174 29.2 233 19.8 941 80.2
Poverty 0.107
Low poverty (0%–7.9%) 899 22.4 135 15.0 764 85.0
Below US average (8%–14.9%) 1228 30.6 230 18.7 998 81.3
Above US average(15%–29.9%) 1425 35.5 263 18.5 1162 81.5
High poverty (30+ %) 462 11.5 78 16.9 384 83.1
High school education 0.004
High level education (85+ %) 698 17.4 95 13.6 603 86.4
About US average (75%−84.9%) 956 23.8 172 18.0 784 82.0
Low level education (65%−74.9%) 1640 40.9 322 19.6 1318 80.4
Very low education (<65%) 720 17.9 117 16.3 603 83.8
Lung cancer Klabunde comorbidity index 0.001
No or very low comorbidity 1501 37.4 258 17.2 1243 82.8
1 1259 31.4 192 15.3 1067 84.7
2 644 16.0 116 18.0 528 82.0
3+ 610 15.2 140 23.0 470 77.0
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observed significantly higher survival among those individu-
als who received any cancer-specific therapy compared with 
their equally comorbid counterparts who did not. Although 
selection bias could have resulted in overestimated mea-
sures of treatment effects in this observational study, our 
data indicate that patients may still derive a survival benefit 
from cancer treatments in the presence of high comorbidity. 
Likewise, we recognize that comorbidity is not a sole factor 
used to decide against treatment in NSCLC patients.
Not all comorbid conditions are expected to have an equal 
impact on the treatment. The most common comorbidities 
in lung cancer patients are chronic obstructive pulmonary 
Figure 2 Survival estimates by comorbidity level and treatment status in stage I and II patients.
Abbreviation: KCI, Klabunde Comorbidity Index.
KCI = index = 3+ treatment = 0
KCI = index = 3+ treatment = 1
KCI = no or very low comorbidity treatment = 0
KCI = no or very low comorbidity treatment = 1
Month_survival
0 20 40
Product-limit survival estimates
60 80
+ Censored
Su
rv
iv
al
 p
ro
ba
bi
lit
y
0.0
0.2
0.4
0.6
0.8
1.0
Figure 3 Survival estimates by comorbidity level and treatment status in stage III patients.
Abbreviation: KCI, Klabunde Comorbidity Index.
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disease, coronary artery disease, congestive heart failure, 
diabetes, and renal insufficiency.4–6 Cardiac comorbidity and 
chronic obstructive pulmonary disease have been described as 
independent risk factors affecting the development of toxic-
ity and the effectiveness of cancer therapy.11–13 In contrast, 
no clear role has been described for other comorbidities 
(such as liver disease or Alzheimer’s dementia) that are also 
included in the construction of the KCI. Moving forward, it 
is important for health care providers and patients to realize 
that, with newer therapeutic options such as immunotherapy, 
organ dysfunction and the comorbidity burden should play a 
lesser role in the decision to treat lung cancer.
There are several limitations to our analysis. The data set 
is from 2007 to 2011 and may not reflect more current prac-
tice patterns. This is particularly important since the recent 
development of immunotherapy, which is believed to have 
a more favorable safety profile and might not be affected by 
comorbidities compared with the safety profile of cytotoxic 
chemotherapy. Given that the study population is restricted 
to Kentucky residents, the results may not be generalizable to 
the US NSCLC population.14–19 The SEER-Medicare database 
does not provide data on other clinically relevant prognostic 
Figure 4 Survival estimates by comorbidity level and treatment status in stage IV patients.
Abbreviation: KCI, Klabunde Comorbidity Index.
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Table 2 Multivariate analysis of factors associated with receiving 
treatment
Variable OR 95% CI p-value
Sex <0.001
Male 1.176 1.096 1.261
Female Ref
Age group (years) <0.001
71–75 1.025 0.936 1.123
76–80 1.284 1.167 1.413
81–85 1.435 1.280 1.607
86+ 1.399 1.186 1.651
66–70 Ref
AJCC stage <0.001
II 1.493 1.257 1.774
III 2.413 2.177 2.673
IV 4.298 3.887 4.752
Unknown 2.365 1.972 2.838
I Ref
Grade <0.001
Moderately differentiated 1.287 1.063 1.556
Poorly differentiated 1.463 1.212 1.767
Undifferentiated 1.705 1.202 2.418
Unknown 1.776 1.478 2.134
Well-differentiated Ref
Comorbidity index <0.001
1 1.122 1.033 1.218
2 1.238 1.104 1.389
3 1.513 1.363 1.679
No or very low comorbidity Ref
Treatment status <0.001
No 2.474 2.259 2.708
Yes Ref
Histology type 0.007
Squamous 1.031 0.958 1.109
Other 1.285 1.100 1.502
Adenocarcinoma Ref
Abbreviation: AJCC, American Joint Committee on Cancer.
Table 3 OS HR untreated vs. treated in each KCI category
KCI 0 KCI 1 KCI 2 KCI ≥ 3
OS (HR)
Untreated
vs
treated 
HR 3.47 
P<0.001, 
95% CI 
(3.0–3.9)
HR 3.05
P<0.001, 
95% CI 
(2.5–3.6)
HR 3.05 
P<0.001 
95% CI 
2.5–3.6
HR 3.12 
P<0.001 
95% CI 
(2.5–3.8)
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factors, including performance status and weight loss, or 
nonclinical factors, such as access to care and social support. 
The lack of ability to account for the potential confounding 
effect of these factors could have biased our results.
Conclusion
NSCLC patients with higher comorbidity burden are less likely 
to receive cancer-specific treatment and more likely to die. 
However, it appears that even in individuals with high comor-
bidity burden, cancer-specific treatments seem to improve 
survival, independently of their stage at presentation. The 
treatment benefit observed in the high comorbid population 
is likely a result of multiple factors, including the treatment 
itself. The impact of comorbidity along with performance 
status, medical and social support system, and the presenting 
stage play an important role in decision to treat lung cancer.
Acknowledgment
This study was supported by Kentucky Lung Cancer Educa-
tion and Survivorship Grant (LEADS).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM.
Natural history of stage I non-small cell lung cancer: implications for
early detection. Chest. 2007;132(1):193–199.
2. Goulart BH, Reyes CM, Fedorenko CR, et al. Referral and treatment
patterns among patients with stages III and IV non-small-cell lung
cancer. J Oncol Pract. 2013;9(1):42–50.
3. Small AC, Tsao CK, Moshier EL, et al. Prevalence and characteristics 
of patients with metastatic cancer who receive no anticancer therapy.
Cancer. 2012;118(23):5947–5954.
4. Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity
and survival in lung cancer patients. Cancer Epidemiol Biomarkers
Prev. 2015;24(7):1079–1085.
5. Tammemagi CM, Nesulund-Dudas C, Simoff M, Kvale P. Impact of
comorbidity on lung cancer survival. Int J Cancer. 2003;103(6):792–802.
6. Grose D, Devereux G, Milroy R. Comorbidity in lung cancer: important
but neglected. a review of the current literature. Clin Lung Cancer. 
2011;12(4):207–211.
7. Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation
on the status of cancer, 1975–2010, featuring prevalence of comorbidity 
and impact on survival among persons with lung, colorectal, breast, or 
prostate cancer. Cancer. 2014;120(9):1290–1314.
8. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comor-
bidity index using physician claims data. J Clin Epidemiol. 2000;53(12): 
1258–1267.
9. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mel-
lemgaard A, Møller H. The effect of comorbidity on stage-specific
survival in resected non-small cell lung cancer patients. Eur J Cancer. 
2012;48(18):3386–3395.
10. Mellemgaard A, Luchtenborg M, Iachina M, et al. Role of comorbid-
ity on survival after radiotherapy and chemotherapy for nonsurgically
treated lung cancer. J Thorac Oncol. 2015;10(2):272–279.
11. Nalbantov G, Kietselaer B, Vandecasteele K, et al. Cardiac comorbidity 
is an independent risk factor for radiation-induced lung toxicity in lung 
cancer patients. Radiother Oncol. 2013;109(1):100–106.
12. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexist-
ing COPD on survival of patients with early-stage non-small cell lung 
cancer undergoing surgical resection. Chest. 2014;145(2):346–353.
13. Lee SJ, Lee J, Park YS, et al. Impact of chronic obstructive pulmonary 
disease on the mortality of patients with non-small-cell lung cancer.
J Thorac Oncol. 2014;9(6):812–817.
14. Gadgeel SM, Kalemkerian GP. Racial differences in lung cancer. Cancer
Metastasis Rev. 2003;22(1):39–46.
15. Patel JD, Socinski MA, Garon EB et al. PointBreak: a randomized phase 
III study of pemetrexed plus carboplatin and bevacizumab followed
by maintenance pemetrexed and bevacizumab versus paclitaxel plus
carboplatin and bevacizumab followed by maintenance bevacizumab in 
patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. 
J Clin Oncol. 2013;31(34):4349–4357.
16. Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-
pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for
advanced nonsquamous nonsmall-cell lung cancer: updated survival
analysis of the AVAPERL (MO22089) randomized phase III trial. Ann
Oncol. 2014;25(5):1044–1052.
17. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study compar-
ing cisplatin plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy- naive patients with advanced-stage non-small-cell lung 
cancer. J Clin Oncol. 2008;26(21):3543–3451.
18. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a
randomised, phase III study of erlotinib versus chemotherapy as first-
line treatment of EGFR mutation-positive advanced non-small-cell
lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):
1877–1883.
 19. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group
in collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica. Erlotinib versus standard
chemotherapy as first-line treatment for European patients with advanced 
EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multi-
centre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):
239–246.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Cancer Management and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Rios et al
Supplementary materials
Table S1 Identification of claims for radiotherapy (the following table shows the code values that were used for searching lung cancer 
radiotherapy under different types of radiotherapy codes)
Medicare file name Type of code
MedPAR Diagnosis codes only
Procedure codes only
NCH Diagnosis codes only
CPT and HCPCS codes
Outpatient Diagnosis codes only
CPT and HCPCS codes
Revenue center
Type of radiotherapy code Code values
ICD-9 diagnosis codes V580, V661,V671
ICD-9 procedure codes 9221–9229
HCPCS codes 77261–77299, 77300–77399, 77401–77499, 77520, 77523, 76370, 76950, 77750–77799, C1325, 
C1348, C1350, C1700–C1712, C1715–C1720, C1728, C1790–C1806, C2616, C2632, C2633, 
C9714, C9715,
G0174, G0178, G0179, G0261, G0256, G0273, G0274, G0338–G0340
Revenue code 0330, 0333
Abbreviations: CPT, Current Procedure Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD, International Classification of Diseases; MedPAR, 
Medicare Provider Analysis and Review; NCH, National Claims History.
Table S2 Identification of claims for chemotherapy (the following tables show the code values that were used for searching lung 
cancer chemotherapy)
Medicare file name Type of code
MedPAR Diagnosis codes only
Procedure codes only
NCH Diagnosis codes only
CPT and HCPCS codes
Outpatient Diagnosis codes only
CPT and HCPCS codes
DME Diagnosis codes only
CPT and HCPCS codes
National Drug Code
Type of chemotherapy code Code values
ICD-9 diagnosis codes V662, V581, V5811, V5812
ICD-9 procedure codes 0010, 1770, 9925, 9928
HCPCS codes 51720, 96400, 51720, 96400, 96401, 96402, 96405, 96406, 96408, 96409, 96410, 96411, 96412, 
96413, 96414, 96415, 96416, 96417, 96420, 96422, 96423, 96425, 96440, 96445, 96446, 96450, 
96520, 96521, 96522, 96523, 96530, 96542, 96545, 96549, 36823, 61517, 95990, 95991, 0519F, 
C8953, C8954, C8955, G0355, G0357, G0358, G0359, G0360, G0361, G0362, G0370, J7150, 
Q0083, Q0084, Q0085, S5019, S5020, S9329, S9330, S9331, S9425, C1086, C1166, C1167, 
C1178, C9012, C9110, C9127, C9205, C9213, C9214, C9215, C9217, C9218, C9235, C9257, 
C9262, C9414, C9415, C9417, C9418, C9419, C9420, C9421, C9422, C9423, C9424, C9425, 
C9426, C9427, C9429, C9431, C9432, C9433, C9437, C9440, J0594, J0894, J8510, J8520, 
J8521, J8530, J8560, J8565, J8600, J8610, J8700, J8705, J8999, J9000, J9001, J9010, J9017, J9020, 
J9025, J9027, J9033, J9035, J9040, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, 
J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, 
J9150, J9151, J9170, J9171, J9178, J9180, J9181, J9182, J9185, J9190, J9200, J9201, J9206, J9207, 
J9208, J9211, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, 
J9290, J9291, J9293, J9300, J9303, J9305, J9307, J9310, J9315, J9320, J9328, J9330, J9340, J9350, 
J9351, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9999, Q2017, Q2024, S0087, S0088, 
S0115, S0116, S0172, S0176, S0178, S0182
(Continued)
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Type of chemotherapy code Code values
NDC codes 00004110013, 00004110020, 00004110022, 00004110051,
00004110113, 00004110116, 00004110150, 00004110151,
00005450704, 00005450705, 00005450707, 00005450709,
00005450723, 00005450791, 00015050301, 00015050302,
00015050401, 00015309145, 00054412925, 00054413025,
00054455015, 00054455025, 00054808925, 00054813025,
00054855003, 00054855005, 00054855006, 00054855007,
00054855010, 00054855025, 00081004535, 00085124401,
00085124402, 00085124801, 00085124802, 00085125201,
00085125202, 00085125901, 00085125902, 00173004535,
00173071325, 00182153901, 00182153995, 00364249901,
00364249936, 00378001401, 00378001450, 00378326694,
00536399801, 00536399836, 00555057202, 00555057235,
00555057245, 00555057246, 00555057247, 00555057248,
00555057249, 00555092701, 00555092801, 00555092901,
00555094501, 00603449921, 00677161001, 00781107601,
00781107636, 00904174960, 00904174973, 51079067005,
51079096505, 51285050902, 54569571700, 54868414300,
54868414301, 54868414302, 54868414303, 54868526000,
54868526001, 54868526002, 54868526003, 54868526004,
54868526005, 54868526006, 54868526007, 54868526008,
54868526009, 59911587401, 62701094036, 62701094099
Abbreviations: CPT, Current Procedure Terminology; DME, durable medical equipment; HCPCS, Healthcare Common Procedure Coding System; ICD, International 
Classification of Diseases; MedPAR, Medicare Provider Analysis and Review; NCH, National Claims History; NDC, National Drug Code.
Table S2 (Continued)
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
